Autolus Therapeutics plc (NASDAQ:AUTL) Sees Large Increase in Short Interest

Autolus Therapeutics plc (NASDAQ:AUTL) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 9,110,000 shares, an increase of 8.7% from the January 15th total of 8,380,000 shares. Based on an average trading volume of 1,710,000 shares, the short-interest ratio is currently 5.3 days.

Institutional Trading of Autolus Therapeutics

Hedge funds have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in Autolus Therapeutics in the fourth quarter valued at about $26,000. Barclays PLC boosted its stake in shares of Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company’s stock valued at $28,000 after buying an additional 10,866 shares during the period. Dumont & Blake Investment Advisors LLC acquired a new position in Autolus Therapeutics during the 4th quarter worth approximately $35,000. Arkadios Wealth Advisors acquired a new position in Autolus Therapeutics during the 4th quarter worth approximately $47,000. Finally, Capstone Investment Advisors LLC purchased a new stake in Autolus Therapeutics during the third quarter worth approximately $51,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on AUTL. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a research report on Friday, November 15th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Price Performance

Shares of NASDAQ:AUTL traded up $0.10 during midday trading on Friday, hitting $2.04. The company had a trading volume of 1,398,801 shares, compared to its average volume of 1,046,105. Autolus Therapeutics has a twelve month low of $1.87 and a twelve month high of $7.31. The business’s 50-day simple moving average is $2.31 and its 200-day simple moving average is $3.27.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.